Home IPO candidate Atara shifts in deal with Memorial Sloan Kettering
 

Keywords :   


IPO candidate Atara shifts in deal with Memorial Sloan Kettering

2014-09-24 04:26:07| Biotech - Topix.net

Isaac Ciechanover's Atara Biotherapeutics has an option to license three experimental drug programs from Memorial Sloan Kettering Cancer Center. IPO-ready Atara Biotherapeutics could license from Memorial Sloan Kettering Cancer Center three treatments already in human clinical trials for certain cancers and persistent viral infections, the company said Tuesday.

Tags: deal candidate memorial ipo

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
22.07Carpetright set for rescue but jobs are at risk
22.07Ryanair slashes summer fares as profits slide
22.07Government to explain Harland and Wolff decision
22.07BT fined millions for failing to connect 999 calls
22.07Eastern North Pacific Tropical Weather Outlook
22.07Atlantic Tropical Weather Outlook
22.07'Significant number' of devices back up - CrowdStrike
22.07IT working but delays possible after outage, says NHS
More »